Related Experiment Videos
[Monoclonal antibody induces apoptosis against cancer cells]
1First Department of Internal Medicine, Sapporo Medical University.
Abstract:
ErbB-2, a member of the epidermal growth factor(EGF) receptor tyrosine kinase family, is often overexpressed and/or amplified in breast, ovarian and gastric cancers, and other malignancies. ErbB-2 is a candidate as one of the best target molecules for cancer therapy. Many anti-ErbB-2 monoclonal antibodies(MoAbs) have been developed. An inhibitory humanized MoAb shows clinical responses in some breast cancer patients, both with MoAb alone and in combination with Cisplatinum or other anti-cancer drugs. A mouse-human chimeric anti-ErbB-2 MoAb CH401 was established and characterized in our laboratory. CH401 is able to kill cancer cells overexpressing ErbB-2 both in vitro and in vivo. The analysis of this tumor growth inhibition by CH401 made it clear that the cytotoxicity was induced by apoptosis. These results may suggest that CH401 has a therapeutic potential for ErbB-2 overexpressing cancers. This approach may be particularly valuable as a new type of cancer therapy.
Insights
A novel chimeric antibody, CH401, effectively targets ErbB-2 overexpressing cancer cells, inducing apoptosis for potential new cancer therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Context:
- ErbB-2 receptor tyrosine kinase is frequently overexpressed in breast, ovarian, and gastric cancers.
- Targeting ErbB-2 is a promising strategy for cancer therapy.
- Monoclonal antibodies (MoAbs) are actively being developed to target ErbB-2.
Purpose:
- To characterize a mouse-human chimeric anti-ErbB-2 MoAb, CH401.
- To evaluate the in vitro and in vivo efficacy of CH401 against ErbB-2 overexpressing cancers.
- To elucidate the mechanism of action of CH401-induced tumor growth inhibition.
Summary:
- CH401, a chimeric anti-ErbB-2 monoclonal antibody, was developed and characterized.
- CH401 demonstrated the ability to eliminate cancer cells overexpressing ErbB-2 in both in vitro and in vivo models.
- Tumor growth inhibition mediated by CH401 was found to be induced by apoptosis.
Impact:
- CH401 exhibits therapeutic potential for ErbB-2 overexpressing malignancies.
- This antibody represents a novel therapeutic approach for targeted cancer treatment.
- Further development of CH401 could lead to new treatment options for patients with ErbB-2 positive cancers.